The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The future of MPN treatment: moving towards combination therapies
John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, comments on the direction of research in myeloproliferative neoplasms (MPNs), particularly the interest in combination approaches with JAK inhibitors. Dr Mascarenhas highlights the success of pelabresib, which is being investigated in combination with ruxolitinib for myelofibrosis (MF) in the MANIFEST-2 study (NCT04603495). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
